Literature DB >> 24009132

Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.

Marina Marchetti1, Carmen J Tartari, Laura Russo, Marina Panova-Noeva, Annamaria Leuzzi, Alessandro Rambaldi, Guido Finazzi, Barry Woodhams, Anna Falanga.   

Abstract

This study evaluates the functional procoagulant features of plasma microparticle (MP) to explore the MP contribution to the hypercoagulable state of patients with essential thrombocythemia (ET). Platelet-free plasma samples were obtained from 73 ET patients (37 positive for the JAK2V617F mutation) and 72 control subjects. The calibrated automated thrombogram (CAT) was performed in plasma samples to determine thrombin generation of MP-associated tissue factor (TF) and procoagulant phospholipid (PPL) activity, and the STA Procoag PPL assay to measure MP-PPL activity only. Both thrombin generation and PPL procoagulant activities were found significantly elevated in ET patients compared to controls, and were associated to significantly higher levels of TF antigen and FVIIa/AT complex. Thrombin generation was significantly greater in JAK2-V617F positive compared to JAK2-V617F negative patients and normal subjects. Significant correlations were found between the PPL-assay and the different parameters of the CAT assay. No difference was seen between the thrombosis and no thrombosis group. Prospective studies are needed to test whether MP-associated thrombin generation and procoagulant activity may predict for thrombosis in these patients.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24009132      PMCID: PMC3946818          DOI: 10.1002/ajh.23590

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  25 in total

1.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

Authors:  A Falanga; M Marchetti; V Evangelista; A Vignoli; M Licini; M Balicco; S Manarini; G Finazzi; C Cerletti; T Barbui
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

2.  Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Authors:  Alessandra Carobbio; Guido Finazzi; Vittoria Guerini; Orietta Spinelli; Federica Delaini; Roberto Marchioli; Giovanna Borrelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

3.  The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

Authors:  Betty Cheung; Deepti Radia; Panagiotis Pantelidis; Ghasem Yadegarfar; Claire Harrison
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

Review 4.  Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.

Authors:  Anna Falanga; Marina Marchetti; Tiziano Barbui; C Wayne Smith
Journal:  Semin Hematol       Date:  2005-10       Impact factor: 3.851

Review 5.  [Chronic myeloproliferative disorders. The new WHO classification].

Authors:  J Thiele; H M Kvasnicka
Journal:  Pathologe       Date:  2001-11       Impact factor: 1.011

6.  V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Authors:  Anna Falanga; Marina Marchetti; Alfonso Vignoli; Donatella Balducci; Laura Russo; Vittoria Guerini; Tiziano Barbui
Journal:  Exp Hematol       Date:  2007-05       Impact factor: 3.084

7.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

8.  Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.

Authors:  Marina Marchetti; Elisabetta Castoldi; Henri M H Spronk; René van Oerle; Donatella Balducci; Tiziano Barbui; Jan Rosing; Hugo Ten Cate; Anna Falanga
Journal:  Blood       Date:  2008-09-03       Impact factor: 22.113

9.  Microparticles in health and disease.

Authors:  Anoop K Enjeti; Lisa F Lincz; Michael Seldon
Journal:  Semin Thromb Hemost       Date:  2008-12-15       Impact factor: 4.180

10.  Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

Authors:  Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán; Juan Carlos Reverter; Neus Villamor; Dolors Colomer; Francisco Cervantes
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

View more
  23 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 2.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

3.  Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond.

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-17       Impact factor: 0.900

4.  Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.

Authors:  Agnès Charpentier; Aurélien Lebreton; Antoine Rauch; Anne Bauters; Nathalie Trillot; Oliver Nibourel; Véronique Tintillier; Mathieu Wemeau; Jean-Loup Demory; Claude Preudhomme; Brigitte Jude; Thomas Lecompte; Nathalie Cambier; Sophie Susen
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

5.  A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

Authors:  Claire Pluchart; Coralie Barbe; Gael Poitevin; Sandra Audonnet; Philippe Nguyen
Journal:  J Thromb Thrombolysis       Date:  2020-11-28       Impact factor: 2.300

6.  Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms.

Authors:  Wenjuan Zhang; Jiaqian Qi; Shixiang Zhao; Wenhong Shen; Lan Dai; Wei Han; Man Huang; Zhaoyue Wang; Changgeng Ruan; Depei Wu; Yue Han
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

Review 7.  Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.

Authors:  Alexandre Guy; Johanne Poisson; Chloe James
Journal:  Leukemia       Date:  2021-03-03       Impact factor: 11.528

8.  Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates.

Authors:  Bérangère Devalet; Adeline Wannez; Nicolas Bailly; Lutfiye Alpan; Damien Gheldof; Jonathan Douxfils; Véronique Deneys; Benoît Bihin; Bernard Chatelain; Jean-Michel Dogné; Christian Chatelain; François Mullier
Journal:  Blood Transfus       Date:  2017-03-09       Impact factor: 3.443

Review 9.  Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.

Authors:  Mohsen Maleknia; Saeid Shahrabi; Majid Ghanavat; Tina Vosoughi; Najmaldin Saki
Journal:  Mol Biol Rep       Date:  2020-05-30       Impact factor: 2.316

10.  The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.

Authors:  Mohamed Hussam Aswad; Jarmila Kissova; Petra Ovesna; Lucie Rihova; Miroslav Penka
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.